Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy-Reference-Cited by-同舟云学术

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy

Published:2022-09 Issue: Volume:30 Page:377-383
ISSN:2213-7165
Container-title:Journal of Global Antimicrobial Resistance
language:en
Short-container-title:Journal of Global Antimicrobial Resistance

Author:

Morroni Gianluca^ORCID,Brescini Lucia,Antonelli Alberto^ORCID,Di Pilato Vincenzo,Castelletti Sefora,Brenciani Andrea^ORCID,D'Achille Gloria,Mingoia Marina,Giovanetti Eleonora,Fioriti Simona,Masucci Annamaria,Giani Tommaso,Giacometti Andrea,Rossolini Gian Maria,Cirioni Oscar

Publisher

Elsevier BV

Subject

Microbiology (medical),Immunology,Immunology and Allergy,Microbiology

Reference36 articles.

1. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence;Moradali;Front Cell Infect Microbiol,2017

2. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections;Horcajada;Clin Microbiol Rev,2019

3. An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the north of England: challenges of infection prevention and control in a complex setting;Decraene;J Hosp Infect,2018

4. Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak;Buhl;Front Microbiol,2019

5. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations;van Duin;Clin Infect Dis,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Vitek® Reveal™ system for rapid antimicrobial susceptibility testing of Gram-negative pathogens, including ESBL, CRE and CRAB, from positive blood cultures;Diagnostic Microbiology and Infectious Disease;2024-12

2. Evaluation of Quantamatrix dRASTTM system for rapid antimicrobial susceptibility testing of bacterial isolates from positive blood cultures, in comparison with commercial Micronaut broth microdilution system;Diagnostic Microbiology and Infectious Disease;2024-09

3. Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study;Microbiology Spectrum;2024-08-06

4. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis;Clinical Microbiology and Infection;2024-02

5. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model;Journal of Antimicrobial Chemotherapy;2023-08-01